Skip to main content

Table 1 Baseline characteristics of COVID-19 patients and controls

From: Dialysis circuit clotting in critically ill patients with COVID-19 infection

 

COVID-19

Control

p-value

Number of CKRT circuits

70

22

Not applicable

Number of patients

12

15

CKRT circuits per patient

10 (2, 10)

2 (2, 3.5)

Duration of CKRT, days

6.5 (3, 17.5)

3 (2, 3.5)

Number of circuits per patient-day of CKRT

0.79 (0.49, 1.15)

1 (0.78, 1)

Number of intermittent dialysis sessions

32

18

Age, years

65 ± 14

58 ± 9

0.16

Male gender, n (%)

9 (75)

13 (87)

0.39

ESKD, n (%)

2 (17)

8 (53)

0.10

Weight, kg

69 ± 17

73 ± 18

0.56

SOFAa

10 ± 5

8 ± 4

0.23

Comorbidities

 HTN, n (%)

8 (67)

10 (67)

1.00

 IHD, n (%)

4 (33)

10 (67)

0.13

 DM, n (%)

2 (17)

11 (73)

< 0.05

Baseline medication use

 Antiplatelet, n (%)

3 (25)

8 (53)

0.43

 Anticoagulantb, n (%)

1 (8)

1 (7)

 
  1. Abbreviations: CKRT Continuous kidney replacement therapy, ESKD End stage kidney disease, SOFA Sequential organ failure assessment, HTN Hypertension, IHD Ischemic heart disease, DM Diabetes mellitus
  2. a SOFA score, is taken at time of dialysis initiation
  3. b Any vitamin K antagonists, direct acting oral anticoagulants or low molecular weight heparin